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The human monoamine transporters (MATs) facilitate the reuptake of the
neurotransmitters serotonin, dopamine, and norepinephrine from the synaptic cleft.
Imbalance in monoaminergic neurotransmission is linked to various diseases including
major depression, attention deficit hyperactivity disorder, schizophrenia, and Parkinson’s
disease. Inhibition of the MATs is thus an important strategy for treatment of
such diseases. The MATs are sodium-coupled transport proteins belonging to the
neurotransmitter/Na+ symporter (NSS) family, and the publication of the first high-
resolution structure of a NSS family member, the bacterial leucine transporter LeuT, in
2005, proved to be a major stepping stone for understanding this family of transporters.
Structural data allows for the use of computational methods to study the MATs,
which in turn has led to a number of important discoveries. The process of substrate
translocation across the membrane is an intrinsically dynamic process. Molecular
dynamics simulations, which can provide atomistic details of molecular motion on ns
to ms timescales, are therefore well-suited for studying transport processes. In this
review, we outline how molecular dynamics simulations have provided insight into the
large scale motions associated with transport of the neurotransmitters, as well as
the presence of external and internal gates, the coupling between ion and substrate
transport, and differences in the conformational changes induced by substrates and
inhibitors.
Keywords: molecular dynamics, monoamine transporters, serotonin transporter, dopamine transporter,
norepinephrine transporter
INTRODUCTION
The human monoamine transporters (MATs) are responsible for the reuptake of monoamine
neurotransmitters in presynaptic neurons (Giros et al., 1996; Bengel et al., 1998; Xu et al.,
2000). There are three diﬀerent plasma membrane bound MATs, each named according to their
main substrate (Figure 1), namely the human serotonin transporter (hSERT), the dopamine
transporter (hDAT), and the norepinephrine transporter (hNET), all of which utilize the
Na+ concentration gradient across the membrane to facilitate transport (Gu et al., 1994).
Imbalance in neurotransmitter homeostasis is linked to diseases such as major depression, anxiety
disorders, attention deﬁcit hyperactivity disorder, schizophrenia, Parkinson’s disease, and obesity
(Kristensen et al., 2011), and MATs are thus important pharmaceutical targets. In particular,
the treatment of depression has been focused on modulating monoamine neurotransmission,
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FIGURE 1 | The monoamine neurotransmitters. The chemical structure of
each of the three monoamine neurotransmitters.
often through inhibition of MATs (Immadisetty et al., 2013).
This has resulted in the development of tricyclic antidepressants
(TCAs) which target all three MATs as well as selective
serotonin reuptake inhibitors (SSRIs) and serotonin and
norepinephrine reuptake inhibitors (SNRIs) (Andersen et al.,
2009a). Additionally, a number of addictive, illicit drugs,
including cocaine and amphetamine, also bind to MATs, and
the transporters are thus also considered as potential targets for
treating drug addiction (Howell and Kimmel, 2008). During the
last decade computational methods have become a prominent
tool for investigating MATs in atomic detail. In this review,
we will highlight how computational molecular dynamics (MD)
studies have been used to generate hypotheses and guide
experiments, leading to insight in to how these transporters
function with respect to binding of substrates, inhibitors and ions,
as well as the intricate details of the mechanism of transport.
These insights will not only help guide the development of new
drugs with fewer side eﬀects and an improved eﬃcacy, but a
greater understanding of the transport process conducted by the
MATs will also aid in developing new treatment strategies for
less understood diseases, thus improving the lives of the millions
of people suﬀering from mental disorders and obesity world
wide.
TOPOLOGY AND STRUCTURE OF MATs
To this day, no high-resolution structures of the human MATs
are available, and the structural knowledge of human MATs is
therefore based on knowledge obtained from other homologous
Na+-coupled transporters (Manepalli et al., 2012). In this regard,
homology models of MATs have yielded unprecedented insight
into the structure–function relationship of these transporters
by allowing direct observation of possible binding motifs of
ligands in the diﬀerent transporters (Koldsø et al., 2015). These
direct observations can then be validated using experimental
techniques such as mutational studies and observation of
accessibility and dynamics using, e.g., ﬂuorescent probes. Early
attempts to model hSERT, hDAT, and hNET were based on
crystal structures of distant relatives such as the Na+/H+
antiporter NhaA and the lactose permease LacY (Ravna et al.,
2003a,b; Ravna et al., 2006; Jaroñczyk et al., 2008). However,
a major breakthrough in the ﬁeld occured in 2005 when the
ﬁrst crystal structure of an NSS family member, namely the
1.65 Å structure of the bacterial leucine transporter (LeuT) from
Aquifex aeolicus, was reported (Yamashita et al., 2005). LeuT
has an overall ∼20–25% sequence identity with the human
MATs and a ∼50% sequence identity for the residues within a
5 Å radius around the central substrate binding site (Beuming
et al., 2006; Koldsø et al., 2013a), making it a reasonable
template for modeling the mammalian MATs, in particular with
regards to substrate and ligand binding. Although the ﬁrst
crystal structure of LeuT resulted in a quantum leap in the
understanding of the structure–function relationship of MATs,
the diﬀerences between eukaryotic and bacterial transporters
still make it diﬃcult to study certain aspects of the MATs. In
particular, the eukaryotic members of the NSS family generally
have longer C- and N-terminal sections compared to their
bacterial counterparts as well as phosphorylation sites and
post-translational modiﬁcations which are not present in the
prokaryotic structures (Pramod et al., 2013). Recently, the ﬁrst
high-resolution structure of a eukaryotic MAT was published
in the form of a 2.95 Å resolution crystal structure of the
dopamine transporter from Drosophila melanogaster (dDAT;
Penmatsa et al., 2013), which opens up new possibilities for a
deeper understanding of eukaryotic transporters from the NSS
family.
Both the LeuT and dDAT structures contain intracellular
N- and C-termini, 12 transmembrane helices (TMs) named
TM1-12 (Figures 2A,B), as well as six extracellular and ﬁve
intracellular loops (EL1-6 and IL1-5). The ﬁrst ten TMs are
arranged in a pseudo-symmetric fold, known as the LeuT-fold,
in which TM1-5 has the same overall internal arrangement
as TM6-10 (Yamashita et al., 2005; Forrest et al., 2008). The
primary substrate binding site is located in the center of the
transporter and is formed by TM1, TM3, TM6, and TM8.
The transport mechanism of secondary active transporters,
such as those in the NSS family, is thought to follow the
alternating access mechanism (Jardetzky, 1966), entailing that the
transporter alternates between conformational states, in which
the substrate binding site is accessible either from one side
of the membrane or the other. LeuT has been crystallized in
both outward- and inward-facing states (Yamashita et al., 2005;
Singh et al., 2008; Krishnamurthy and Gouaux, 2012), whereas
crystal structures of dDAT capture the transporter in an outward-
open or outward-occluded state (Penmatsa et al., 2013; Wang
et al., 2015) (Figure 3). Based on the crystal structure of the
outward-facing conformation of LeuT, and the observed pseudo-
symmetry of the LeuT-fold, Forrest et al. (2008) proposed a
structure of the inward-facing conformation of LeuT (Forrest
et al., 2008) prior to the capture of this state in LeuT crystal
structures. A comparison of the outward- and inward-facing
conformation then led to the formulation of the rocking bundle
transport mechanism (Forrest and Rudnick, 2009). According
to this mechanism four of the TMs, two from each inverted
repeat (TM1, TM2, TM6, TM7), form a bundle which is partly
surrounded by six helices, three from each inverted repeat (TM3-
5, TM8-10), which acts as a stationary scaﬀold. The bundle
helices are hypothesized to rock back and forth resulting in
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FIGURE 2 | The topology of the LeuT-fold and the structure of dDAT. (A) A schematic view of the topology of the 12 TMs in dDAT. TM1-5 and TM6-10 are
related by a pseudo twofold rotation as indicated by the gray triangles. (B) The structure of dDAT as observed in the X-ray crystal structure with dopamine bound
[PDB code 4XP1 (Wang et al., 2015)]. The structure is colored according to the coloring shown in the schematic in part A of this figure. Dopamine in the central
binding site is shown in black spheres. The black lines represent the approximate position of the membrane.
the central binding site alternating between being accessible to
the extra- or intracellular environment (Figure 3). Additionally,
a two-substrate mechanism has been proposed for LeuT-fold
transporters (Shi et al., 2008; Shan et al., 2011). This mechanism
entails that binding of a second substrate in a binding site in
the extracellular vestibule is necessary for triggering the release
of substrate from the primary binding site to the intracellular
milieu.
FIGURE 3 | The transport cycle. Four of the conformational states in the transport cycle that have been captured in crystal structures of NSS family members are
shown as cut-through surfaces. For each state, TM1 and TM6 in the bundle and TM3 and TM8 in the scaffold are shown in red, green, yellow, and blue, respectively.
For the outward occluded and inward occluded state, the substrate is shown as spheres with the carbon atoms in pink. The figure is based on the following crystal
structures: outward occluded; LeuT, PDB code 2A65 (Yamashita et al., 2005). Inward occluded; MhsT, PDB code 4US3 (Malinauskaite et al., 2014). Inward open;
LeuT, PDB code 3TT3 (Krishnamurthy and Gouaux, 2012). Outward open; LeuT, PDB code 3TT1 (Krishnamurthy and Gouaux, 2012).
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SUBSTRATE, ION, AND INHIBITOR
BINDING
The Primary Substrate Binding Site
The binding interactions of the endogenous substrates have been
thoroughly examined using computational methods. All three
substrates share similar primary binding interactions, and in fact
the substrates can also to some extent be transported by some
of the other transporters (Gu et al., 1994; Zhou et al., 2005;
Larsen et al., 2011). The substrates are believed to carry a positive
charge at their primary amine when they are transported (Keyes
and Rudnick, 1982; Berﬁeld et al., 1999) and are thus capable of
forming a salt bridge with a negatively charged aspartate present
in the binding site (Barker et al., 1999). In all three binding sites
the majority of residues are hydrophobic (Figure 4); however, a
few polar residues are able to form stronger interactions with the
substrates (Koldsø et al., 2013a), a feature which can be exploited
when designing selective ligands.
For hSERT, several molecular docking and MD simulation
studies have found that the primary amine in the substrate
serotonin (5-HT) forms a salt bridge with D98 (Jørgensen et al.,
2007; Celik et al., 2008; Gabrielsen et al., 2012), as seen in
Figure 5. The amine in the indole moiety of 5-HT and the
hydroxyl group are expected to participate in hydrogen bonds
FIGURE 4 | Sequence alignment of the regions involved in substrate and ion binding. The alignment has been made using ClustalO. Residues proposed by
MD studies to interact with either substrates or ions are colored accordingly. Residues interacting with more than one substrate/ion are displayed in two colors. The
gray dots represent intervals of ten residues.
FIGURE 5 | Substrate binding sites. The residues proposed to interact with the substrate based on MD studies are shown as thin sticks with the carbon atoms in
orange. In cartoon is shown TM1 (red), TM3 (yellow), TM 6 (green), and TM8 (blue). The substrates are shown in thicker sticks with the carbon atoms in pink for
5-HT, blue for DA, and green for NE. The shaded areas mark interactions between the substrate and the binding site residues. Models of hSERT, hDAT, and hNET
are from (Koldsø et al., 2013a).
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with residues in the transporter binding site; however, multiple
diﬀerent interaction partners have been suggested based on
modeling. Jørgensen et al. (2007) found that the secondary amine
interacts with T439 and the hydroxyl group interacts with G442.
Gabrielsen et al. (2012) found two possible binding modes of
5-HT; one, termed mode A, in which the secondary amine is
located between Y95 and F341 and the hydroxyl group is pointing
toward Y176, S438, and T439, and another one, termed mode B,
in which the indole ring is ﬂipped such that the secondary amine
points toward Y176 and S438 and the hydroxyl group is in the
vicinity of A169 and F341 (Gabrielsen et al., 2012). The latter
binding mode is similar to the one described by Jørgensen et al.
(2007). Gabrielsen et al. (2012) performed MD simulations of
hSERT in complex with 5-HT in each of the two binding modes,
and found that only 5-HT binding in mode B is able to induce
conformational changes in hSERT, and based on this, mode B
was suggested as the most likely binding mode. However, Celik
et al. (2008) found, based on docking studies and an exhaustive
structure–activity relationship study using the paired mutant-
ligand analog complementation approach, that 5-HT binds in
mode A (Celik et al., 2008). This experimentally validated binding
mode has been used in an unbiased MD study of hSERT in which
a substrate-induced conformational change from outward- to
inward-facing was observed (Koldsø et al., 2011), which further
corroborates that mode A is the most likely binding mode for
5-HT.
Similar studies have been performed for hDAT, focusing
both on the primary site and a vestibular site, located ∼10 Å
above the primary binding site. Most homology models have
been constructed based on LeuT template structures, but also
the Na+/H+ antiporter from Escherichia coli (NhaA) (Ravna
et al., 2003b) has been used. Since NhaA has a diﬀerent fold
than LeuT (Forrest et al., 2011), the models based on NhaA
are very diﬀerent from the LeuT-based models and the dDAT
crystal structure, and will thus not be included in the following.
Common for the studies focusing on the primary binding site
is the observation of a salt bridge between the primary amine
of the substrate dopamine (DA) and D79, however, the amine
is also likely interacting with the backbone of F76 (Huang and
Zhan, 2007), S422 (Huang and Zhan, 2007), or F320 (Koldsø
et al., 2013a) through hydrogen bonds. The para-hydroxyl group
is observed to interact with S149 (Koldsø et al., 2013a) or the
backbone of G425 or S422 (Huang and Zhan, 2007) (Figure 5).
Studies of a homology model of the rat DAT (rDAT) showed
similarly that the charged amine of DA interacts with either D79
(corresponding to D79 in hDAT) or the backbone of F76 (F76 in
hDAT) while the para-hydroxyl group interacts with S421 (S422
in hDAT) (Merchant andMadura, 2012). Huang and Zhan (2007)
observed π–π interactions between DA and Y156, and cation-π
interactions between the primary amine of DA and the aromatic
ring system of F76, which has not been reported by other groups.
Two diﬀerent binding modes of DA were found by Koldsø et al.
(2013a) using docking methods where one binding mode was an
180◦ rotation around the long axis of DA compared to the other
binding mode. The two binding modes were distinguishable by
the interaction of themeta-hydroxyl group which was either with
S149 or the backbone of S422. In MD simulations, DA was found
to ﬂuctuate between the two binding modes (Koldsø et al., 2013a).
Thus, it is likely that DA binding to hDAT is rather ﬂexible and
involves shifts between diﬀerent interaction partners. Shan et al.
(2011) reported a binding pattern similar to the one reported by
Huang and Zhan (2007) when performing steered MD (SMD)
simulations of DA being pulled from the primary binding site in
hDAT toward the extracellular milieu.
Very few MD simulation studies have been performed
for hNET. Using both docking and MD simulations Koldsø
et al. (2013a) found that the positively charged amine of
norepinephrine (NE) forms a salt bridge interaction with D75
or a hydrogen bond to F317 similar to the other monoamines
in their respective transporters. Additionally, the meta-hydroxyl
group was found to interact with S420 while the para-hydroxyl
group interacts with the backbone of A145. The hydroxyl group
on the alkyl chain of NE was found to interact with the backbone
of either S419 or F72.
It is evident that it is possible to predict binding modes of
substrates usingmolecular mechanical approaches and to validate
them by use of MD simulations and experimental methods as
demonstrated above. Binding of substrates to MATs appear to
have several features in common such as salt bridge formation to
an aspartate in TM1, hydrogen bonding to polar residues in TM3
and TM8, and hydrophobic interactions with conserved residues
in the binding site as illustrated in Figures 4 and 5.
Ion Binding Sites
Due to the high concentrations of monoamine neurotransmitters
inside neurons, a source of energy is necessary for facilitating
the transport of the monoamine substrates across the membrane
against their concentration gradient. For all three MATs,
transport of substrate is coupled to co-transport of Na+ and
Cl− ions along their concentration gradient (Gu et al., 1994),
while hSERT also requires counter-transport of K+ (Nelson
and Rudnick, 1979). The transport stoichiometry is believed
to be 1:1:1:1 (hSERT), 1:1:1:0 (hNET), and 1:2:1:0 (hDAT) for
substrate/Na+/Cl−/K+ (Talvenheimo et al., 1983; Gu et al., 1994,
1996). Until now, it is only the two Na+ ion binding sites,
known as Na1 and Na2, and the Cl− ion binding site that
have been identiﬁed through X-ray crystallography of LeuT
(Yamashita et al., 2005) and dDAT (Penmatsa et al., 2013), while
the ion binding site for K+ in hSERT remains unidentiﬁed. The
observed coordination geometry in the Na+ ion binding sites
changes between the structures of LeuT and dDAT, suggesting
that the coordination geometry of the Na+ ions might have subtle
diﬀerences between the MATs.
Although only a single Na+ ion is expected to be transported
along with 5-HT in hSERT, it is commonly believed that two
Na+ ions bind to both the Na1 and the Na2 site in hSERT
simultaneously. Early, 17 ns long MD simulations of a hSERT
homology model based on LeuT suggested pentacoordination
of the ion in the Na1 site by the sidechain of residues D98,
N101, and S336 and the backbone carbonyl of A96 and F335
(Figure 6; Jørgensen et al., 2007). However, in several more recent
simulation studies, the Na+ ion in the Na1 site has been observed
to be stably hexacoordinated by the sidechain of D98, N368, and
N101, the backbone carbonyl of A96 as well as both the sidechain
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FIGURE 6 | Ion binding sites. Residues proprosed by MD studies to be involved in ion binding are shown as sticks with the carbon atoms in gray. The residue
indices are given in red for hSERT, blue for hDAT, and green for hNET. The approximate position of each ion is indicated by a sphere. The figure is based on a
homology model of hSERT (Koldsø et al., 2013a).
hydroxyl and backbone carbonyl of S336 (Henry et al., 2011;
Koldsø et al., 2013a; Felts et al., 2014), all of which correspond
to the coordinating residues in the Na1 site of LeuT. For the
Na2 site, pentacoordination involving the backbone carbonyls
of G94 and V97, both sidechain oxygen atoms of D437, and
either the hydroxyl group of S438 (Felts et al., 2014) or the
backbone carbonyl of L434 (Jørgensen et al., 2007) has been
suggested. Additionally, hexacoordination, where both S438 and
L434 participate in the coordination, has also been proposed
(Celik et al., 2008; Koldsø et al., 2011). Since LeuT is a Cl−-
independent transporter, the transporter does not contain a Cl−
ion binding site; however, it has been shown that the side chain
of the residue E290 in LeuT overlaps with the position of the
Cl− ion binding site in the human neurotransmitter transporters
(Forrest et al., 2007; Zomot et al., 2007). Based on this, a number
of diﬀerent coordinating residues and coordinating geometries
have been proposed from MD studies of LeuT-based hSERT
homology models. In the dDAT structures (Penmatsa et al., 2013,
2015; Wang et al., 2015), the bound Cl− ion is coordinated
in a tetrahedral fashion, and it is likely that the corresponding
residues in hSERT, Y121, Q332, S336, and S372, coordinate the
Cl− ion, considering that these four residues are all conserved
among the human MATs and dDAT. In addition, N368 has also
been proposed to be involved in Cl− coordination by several
studies (Celik et al., 2008; Henry et al., 2011; Koldsø et al., 2011;
Felts et al., 2014). Interestingly, it has been found that mutating
N101 in the Na1 site of hSERT to either alanine or cysteine gives
rise to Cl−-independent substrate transport (Henry et al., 2011;
Felts et al., 2014). In MD simulations of wild type hSERT with
and without Cl− bound, it has been observed that lack of Cl−
causes D98 to coordinate only the Na+ ion in the Na1 site in
a bidentate fashion rather than interacting both with the Na+
ion and the charged amine group of 5-HT (Henry et al., 2011;
Felts et al., 2014). On the other hand, simulations of the N101A
mutant with an empty Cl− site display interaction from D98 to
both the Na+ ion and the substrate, which may explain the lack of
Cl− dependence for this mutant. In these simulations it was also
observed that the positioning of S336 and N368, both of which
have been suggested to interact simultaneously with the Cl− ion
and the Na+ ion in the Na1 site, play an important role in ion-
coupled substrate movement. Additionally, the N101A mutation
also allows Ca2+ to substitute for Na+ in terms of facilitating
transport. Based on a combination of biochemical experiments
and MD simulations, it has been suggested that Ca2+ binds in
the Na1 site of the N101A mutant, and is not transported along
with substrate (Felts et al., 2014). The results could indicate that
it is only the Na+ ion in the Na2 site in wild type hSERT that is
co-transported with the substrate and that the role of the Na+ ion
the Na1 site is mainly related to substrate binding.
In the case of hDAT, MD simulations performed by Huang
and Zhan (2007) show that the coordination of the Na+ ions
shifts between penta- and hexacoordination, and that the ratio
between these two coordination geometries change upon DA
binding in the primary binding site. Furthermore, they found
that the coordinating amino acids also diﬀered when performing
simulations of hDAT with and without DA bound. Speciﬁcally,
they ﬁnd that the ion in the Na1 site is coordinated by A77, N82,
S321, F320, and D79 when DA is occupying the primary binding
site, but when the primary binding site is empty the ion in the
Na1 site is primarily hexacoordinated by A77, N82, S321, N353,
S357, and F76, thus changing the coordinating state of the ion
as well as several of the coordinating residues (Huang and Zhan,
2007). However, it should be noted that the simulations were
performed without Cl− bound to hDAT, which is likely to have
aﬀected the results. For instance, S357 is expected to coordinate
Cl− (Penmatsa et al., 2013), and would not be able to coordinate
both Na+ and Cl− simultaneously. Koldsø et al. (2013a) also
found that the ion in the Na1 site is pentacoordinated in a DA-
occupied hDAT model; however, they found that Na+ interacts
with N353 and not F320 as Huang and Zhan observed. For the
ion in the Na2 site, Huang and Zhan (2007) also observed a
change in coordination state caused by the presence of substrate.
When simulations of hDAT were performed in the absence of
DA within the primary binding site, the ion in the Na2 site
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is hexacoordinated by G75, D79, L418, the hydroxyl group of
S422 and both sidechain oxygen atoms of D421 most of the
simulation time. However, whenDA is bound, pentacoordination
by G75, V78, L418, and both sidechain oxygen atoms of D421 is
observed in the majority of the simulation time. When the ion in
the Na2 site shifts to pentacoordination in simulations of hDAT
without DA it is the coordination by S422 that is lost (Huang and
Zhan, 2007). Thus the pentacoordination of the ion in the Na2
site is not the same in simulations of hDAT with and without
DA, as V78 is exchanged for D79 in simulations of hDAT with
DA occupying the primary binding site. Koldsø et al. (2013a)
have reported the ion in the Na2 site to be coordinated by the
same residues as Huang and Zhan (2007) found for DA bound
hDAT, but they only observed an interaction with one of the side
chain oxygen atoms of D421 corresponding to pentacoordination
(Koldsø et al., 2013a) and not hexacoordination as Huang and
Zhan (2007) reported to be most common. A study by Shan et al.
(2011) found that the coordination of the ion in the Na2 site by
L418 was abolished when a DA molecule was placed in both the
primary binding site and the vestibular site of hDAT using SMD.
They found that the change in coordination was due to a rotation
of L418 which makes the sidechain of L418 able to interact with
W84 instead of the Na+ ion. Furthermore, they observe solvation
of the Na2 site from the intracellular side after this change in
coordination, suggesting this change in coordination might be
necessary for inward release of Na+.
The dynamics of the Cl− site in hDAT has to our knowledge
not yet been reported by anyone. However, Koldsø and co-
workers report a tetrahedral coordination of Cl− to Y102, S321,
N353, and S357 in their homology model.
The stabilization of an outward-facing conformation of
hDAT by Zn2+ has been long established (Richﬁeld, 1993), but
the interactions allowing for this eﬀect are less well-known.
A homology model of hDAT has been constructed based on
LeuT for the outward-facing conformation, where the Zn2+
binding site has been used as a restraint in the model making
process (Stockner et al., 2013). This was shown to change the
observed behavior of hDAT in MD simulations, compared to
MD simulations of homology models constructed without focus
on these possible restraints. Based on MD simulations of this
homology model, it was found that the Zn2+ site not only
consisted of H193, H375, and E396 as determined by other
methods, but also included coordination to D206. Furthermore,
the ﬂexibility of EL2 was decreased in this homology model,
and it was observed that the Zn2+ site was broken when the
bundle domain of hDAT rotated as part of the conformational
change needed to shift to the inward-facing conformation of
hDAT. This site disruption was found by combining the new EL2
loop conformation with a structure of LeuT in the inward-facing
conformation (Stockner et al., 2013).
The dynamics of the coordination of the bound Na+ ions
and Cl− ion in hNET have not been reported to our knowledge.
Koldsø et al. (2013a) reports the coordination of the ions in a
homology model that has been energy minimized. They ﬁnd that
the ion in the Na1 site is pentacoordinated by A73, D75, N78,
S318, and N350, while the ion in the Na2 site is pentacoordinated
by G71, V74, L415, D418, and S419. Similar to what has
been suggested for hSERT and hDAT, they observe Cl− to be
tetracoordinated by Y98, S318, N350, and S354.
Several coordination geometries and coordinating residues
in the Na+ and Cl− sites have been proposed based on
homology modeling and MD simulations as illustrated above.
Despite Na+ ion coordination changing between penta- and
hexacoordination, a common motif of binding appears for all ion
sites (Figures 4 and 5), suggesting that the overall coordination
of ions in MATs is similar although not identical. As described
above, it has been possible to observe changes in coordination
geometry of ion sites depending on substrate binding, and to
predict changes in binding site behavior and ion selectivity using
MD simulations. This has led to a greater understanding of the
intricate details governing ion dependent transport.
Inhibitor Binding
The most commonly used antidepressants, such as TCAs,
SSRIs, and SNRIs, all function by inhibiting the MATs, thereby
increasing the monoamine concentration in the synaptic cleft
(Immadisetty et al., 2013). Due to their clinical importance,
there is a great interest in understanding the structural basis
underlying their action. Although crystal structures of LeuT with
either an SSRI or a TCA bound in the extracellular vestibule
have been published (Singh et al., 2007; Zhou et al., 2007, 2009),
evidence from both experimental and computational studies of
the human MATs points toward the inhibitors primarily binding
in the central substrate binding site (Andersen et al., 2009b,
2010, 2011, 2014; Koldsø et al., 2010; Sinning et al., 2010).
In accordance with this, MD simulations of hSERT with the
TCA imipramine (Figure 7) bound in either the central binding
site or the extracellular vestibular binding site have suggested
that imipramine binds stably in the primary site and unstably
in the extracellular vestibule (Sinning et al., 2010). The result
is supported by dDAT crystal structures which include several
types of antidepressants bound in the primary site (Penmatsa
et al., 2013, 2015; Wang et al., 2015), and by the fact that
crystal structures of LeuT-variants, in which the primary site has
been made MAT-like, also display binding of TCAs, SSRIs, and
SNRIs in the primary site (Wang et al., 2013). On the other
hand, it is known that hSERT contains an additional low-aﬃnity
allosteric site, and that binding of ligands in this site aﬀects
the dissociation rate of ligands from the central binding site
(Plenge and Mellerup, 1997). Using a combination of docking,
MD simulations, and mutagenesis, Plenge et al. (2012) showed
that the allosteric site is positioned in the extracellular vestibule.
An iterative approach was used to ﬁnd the optimal binding
mode of the SSRI (S)-citalopram and the TCA clomipramine
(Figure 7) in the extracellular vestibule of hSERT with (S)-
citalopram simultaneously bound in the central binding site.
First, an induced ﬁt docking was performed, followed by an
MD simulation of the top-ranked pose. If unstable binding was
observed during the simulation, the ligand was re-docked into the
MD-altered binding site, and a new simulation was performed.
This was repeated until a stable binding mode was obtained, such
that residues important for binding could be proposed (Plenge
et al., 2012). Based on the results, a number of residues in the
extracellular vestibule were mutated and the majority caused
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FIGURE 7 | Chemical structures of selected MAT inhibitors.
a change in the potency of (S)-citalopram and clomipramine
in inhibiting the dissociation of (S)-citalopram from the high-
aﬃnity central binding site, which validates both the position of
the allosteric site and the proposed binding modes of the two
inhibitors in the allosteric site.
Besides pharmaceutical drugs, MATs are also the targets
of drugs of abuse such as cocaine, amphetamine and 3,4-
methylenedioxy-methamphetamine (commonly known as
‘ecstasy’) (Howell and Kimmel, 2008). Among the MATs, the
primary target of cocaine is hDAT, and there are multiple
MD studies aiming at elucidating its mechanism of inhibition.
The location of the binding site of cocaine in hDAT has
been debated, and several diﬀerent computational as well as
experimental methods have been employed in an attempt to
determine if cocaine binds to the primary binding site or the
vestibular binding site. Merchant and Madura (2012) used
multi-conﬁguration thermodynamic integration (MCTI) to
determine the free energy change needed for a cocaine molecule
to pass through rDAT. The resulting free energy proﬁle showed
an energetic minimum for cocaine in the vestibular site, but
not in the primary binding site. No direct binding interactions
between cocaine and the primary binding site were observed,
and they report cocaine as being too large to ﬁt in the binding
site. Interestingly, they do not report any speciﬁc interactions
between cocaine and rDAT when in the vestibular site either,
but this site is proposed to be able to expand to allow cocaine
binding (Merchant and Madura, 2012). Huang et al. (2009)
investigated cocaine binding to the vestibular binding site in
hDAT while the primary binding site was occupied by DA. They
found cocaine to be able to bind stably throughout 4.5 ns of
MD simulation (Huang et al., 2009), and observed the positively
charged amine of cocaine to be close to Y88, although a direct
cation-π interaction was not seen. Cocaine binding was also
found to be stabilized by interactions with L80, A81, I159,
F155, Y156, and F320 in the vestibular binding site. Based
on this result, it was suggested that DA binds ﬁrst, followed
by cocaine binding in the vestibular site, thus trapping DA
in the primary site while not allowing hDAT to continue the
conformational changes needed to release DA to the cytoplasm.
Dahal et al. (2014) attempted to determine the binding site of
cocaine by performing docking and MD simulations of rDAT
with a cocaine analog, RTI82, bound. They found RTI82 to
bind in the primary binding site with the charged amine stably
interacting with D79 (D79 in hDAT), and the chloro-substituent
close to N157 (N157 in hDAT) throughout 60 ns of MD
simulations. The azidoiodophenyl group is pointing toward
the vestibular site, with the azido group interacting with F319
(F320 in hDAT). Dahal et al. (2014) also performed biochemical
experiments utilizing the ability of RTI82 to covalently attach
to –CH and –NH groups in hDAT upon photoactivation, and
found that RTI82 is able to covalently bind to F320 in hDAT
further supporting their binding hypothesis. They suggest that
the observed binding pattern for RTI82 can be transferred to
cocaine binding in the primary binding site (Dahal et al., 2014).
However, it should be noted that RTI82 is a signiﬁcantly larger
molecule than cocaine (Figure 7), which could suggest that
there may be some diﬀerences in the interaction pattern for
the two compounds. Taken together, MD simulations mainly
indicate that cocaine binds to the vestibular site in hDAT and
rDAT; however, the recent dDAT crystal structure shows cocaine
co-crystalized in the primary binding site (Wang et al., 2015),
suggesting that species-dependent diﬀerences in the mechanism
of inhibition by cocaine could perhaps exists. Alternatively,
the results could indicate that studies based on hDAT in the
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outward occluded state, rather than the outward open state, are
not valid in the context of cocaine binding predictions since
cocaine is too big to bind in this conformation thus leading
to false predictions. Cocaine binding to hSERT has also been
studied using docking and MD simulations; Koldsø et al. (2013b)
showed that cocaine positioned in the central binding site
primarily stabilized an outward-facing conformation during
the simulations, in accordance with what is expected based
on accesability measurements (Zhang and Rudnick, 2006).
Similarly, it was also observed that positioning of noribogaine,
a non-competitive inhibitor of hSERT that traps the transporter
in an inward-facing conformation (Jacobs et al., 2007), in the
primary binding site caused an opening of the transporter to the
intracellular side. These results imply that MD simulations can
be applied to observe inhibitor-induced conformational changes
that are consistent with experimental results and furthermore
substantiates that both noribogaine and cocaine bind in the
primary binding site of hSERT.
While many of the MAT inhibitors, such as SSRIs and cocaine,
competitively inhibit substrate transport, amphetamines function
as exogenous substrates and are believed to be transported by
the MATs from the synaptic cleft to the intracellular space.
Additionally, amphetamines induce substrate eﬄux facilitated by
the MATs, which leads to an increase in the cytosolic monoamine
concentration (Sitte and Freissmuth, 2015). The role of the
N-terminus of MATs in amphetamine action has been studied
by Sucic et al. (2010) using a combination of MD simulations
and biochemical experiments. In this study, it was shown by
mutational experiments that changing T81 in the N-terminus
of hSERT to alanine abolishes para-chloroamphetamine induced
eﬄux of substrate. T81 is part of a stretch of residues that are
conserved among the MATs, and the corresponding mutations
in hDAT and hNET led to similar results. Short MD simulations
of wild type hSERT (3 ns) as well as the in silico T81A
mutant (6 ns), using a homology model in which the ﬁrst
78 residues have been truncated in both setups, showed that
the hydroxyl group of T81 forms a hydrogen bond with the
backbone carbonyl of Y350, which is absent for the T81A
mutant. Additionally, the simulations showed that when the
T81A mutation is introduced, the cytoplasmic end of TM1
moves away from TM6, IL3, and IL2, leading to a more
inward-facing conformation. Furthermore, the distance between
the N- and C-terminus is increased in this mutant during
6 ns of MD simulation (Sucic et al., 2010). Thus, based on
the simulations it could be predicted that ibogaine, which
stabilizes the inward-facing conformation, should have a higher
aﬃnity for the T81A mutant, while imipramine, which stabilizes
the outward-facing conformation should have a lower aﬃnity.
Subsequent experiments using the T81A mutant showed that
the changes in binding aﬃnity for imipramine and noribogaine
predicted by MD simulations could indeed be veriﬁed (Sucic
et al., 2010). Additionally, ﬂuorescence resonance energy transfer
experiments showed an increase in the distance between the N-
and C-terminus for the T81A mutant compared to wild-type
hSERT, which is also in agreement with the results from the MD
simulations. Interestingly, expression of a hSERT variant with the
ﬁrst 64 residues deleted showed that omission of the N-terminal
residues has similar eﬀects on the para-chloroamphetamine
induced eﬄux as the T81A mutant. Overall, the results suggest
that the N-terminus plays a direct role in driving the transporter
into a state that supports eﬄux induced by amphetamines. In
an eﬀort to decipher the mechanism behind this, Khelashvili
et al. (2015) constructed a model of the N-terminus of hDAT
and performed MD simulations of only the N-terminus anchored
to a mixed lipid membrane. It was found that the terminal was
structured in such away that several lysine residues clustered
together and stably interacted with the negatively charged
phosphatidylinositol 4,5-biphosphate lipids in the inner leaﬂet
of the membrane throughout more than 550 ns simulations.
Simulations of the N-terminal with serine to aspartate mutations
that imitate phosphorylation showed a disruption of the
N-terminal anchoring in the membrane suggesting that the
anchored conformation is necessary for amphetamine-induced
eﬄux since phosphorylation of the N-terminal has been shown
to regulate eﬄux (Khelashvili et al., 2015). Phenylpiperazine (PP)
also acts as monoamine releaser. The binding of PP and PP
analogs to hSERT and hDAT has been studied by a combination
of docking, MD simulations and biochemical experiments, and
it was found that this class of compounds binds in the primary
binding pocket of the transporters (Severinsen et al., 2012).
Additionally it was found that both PP and the PP analogs
formed stable interactions with D98 within hSERT during MD
simulations. A PP analog, 3-hydroxyl PP, was found to bind in
two diﬀerent orientations diﬀering by a 180◦ rotation. Both of
these binding modes remained stable in terms of the hydrogen
bonding pattern observed during MD simulations. On the other
hand, the phenyl and the piperazine rings were observed to rotate
with respect to each other in simulations of the unsubstituated PP
while maintaining the saltbridge between the positively charged
amine group of the ligand and D98 in hSERT (Severinsen et al.,
2012).
As demonstrated above, it is possible to observe inhibitor-
induced conformational changes during unbiased MD
simulations despite the computational limitations in simulation
time. In addition, the diﬀerent mechanisms of inhibition
by several classes of inhibitors can be distinguished in MD
simulations allowing great insight into the mechanistic details of
MAT inhibition.
THE TRANSPORT MECHANISM
In spite of progress in determining how neurotransmitters are
transported across the membrane, the molecular mechanism is
still not well-understood. Several conformational states have been
captured in crystal structures of LeuT (Yamashita et al., 2005;
Singh et al., 2008; Krishnamurthy and Gouaux, 2012), dDAT
(Penmatsa et al., 2013, 2015; Wang et al., 2015), and in crystal
structures of LeuT engineered to resemble the central binding
sites in MATs (Wang et al., 2013). However, each structure
only represents a single snapshot in the transport cycle, and the
transition from one state to another cannot readibly be inferred.
However, MD simulations are excellent for obtaining knowledge
on dynamic processes such as possible pathways between two
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conformational states. Both unbiased equilibrium simulations
and simulations biased toward observing speciﬁc events have
proven to be very useful in deciphering the mechanism of action
of MATs.
The Role of Substrate Binding in the
Vestibular Site
It has been debated whether substrate binds only in the primary
binding site of LeuT and MATs (Reyes and Tavoulari, 2011) or
if binding of a second substrate in the extracellular vestibule
(Figure 8) is needed to trigger substrate release from the primary
binding site as has been proposed for LeuT (Shi et al., 2008) and
hDAT (Shan et al., 2011). Several computational methods have
been applied to try to determine this. Merchant and Madura,
(2012) calculated a free energy proﬁle of DA moving through
rDAT using the MCTI method, and found that DA would pass
through an energetic minimum in both the primary and the
vestibular binding site (Merchant and Madura, 2012). However,
when they applied random accelerated MD (RAMD) to assess
the possible release pathways of DA from the primary binding
site, they did not ﬁnd a clear release pathway to the intracellular
side when DA was occupying both binding sites, but they did
observe a clear pathway when performing simulations of rDAT
with DA bound only in the primary binding site. They suggest
that only one DA molecule is needed during transport, and
that the energetic minimum found in the vestibular binding
FIGURE 8 | The vestibular binding site. The gray oval marks the
approximate position of the vestbular binding site, which is shown here for
dDAT [PDB code 4XP1 (Wang et al., 2015)]. The site is flanked by TM1 (red),
TM3 (orange), TM6 (green), TM8 (cyan), TM10 (blue), and EL4 (aquamarine).
EL2 is shown in yellow and the remaining part of the transporter is shown in
white. Dopamine, bound in the central binding site, is shown in black spheres.
site is responsible for moving DA from the extracellular milieu
to the primary binding site, thus serving as a stepping stone
between the solvent and the binding site. An SMD study by
Shan et al. (2011) found that the release of DA to the cytoplasm
was improved by having both the primary and the vestibular
binding site occupied by DA due to an increase in interactions
between DA in the primary site and water molecules from the
cytoplasm when DA is also occupying the vestibular site. Due to
a movement of DA further into the primary site, new interactions
between DA and hDAT are formed. They ﬁnd that EL2 and
EL4 move closer into the vestibular binding site when both
sites were occupied which then pushes the extracellular end
of TM3 in on the vestibular binding site. This was observed
to make I390 and F391 push the sidechain of W84 and L80
toward the primary binding site, in turn making Y156 and F320
rotate and push the DA molecule in the primary site further
downward into its site. This rearrangement of residues causes
L418 to interact with W84 instead of the ion in the Na2 site,
and this switch is proposed to be relevant for ion release (Shan
et al., 2011). For hSERT, MD simulations with substrate bound
in both the primary and the vestibular site display unstable
binding of 5-HT in the vestibular site (Koldsø et al., 2011).
Furthermore, in the same study, a conformational change from
outward- to inward-facing was observed only when a single
substrate was bound in the central binding pocket, which does
not favor a two-substrate allosteric mechanism. Clearly, the
results of performing simulations with substrate in the vestibular
binding site of hSERT and hDAT are not in agreement. Similarly,
experiments on LeuT in regards to the two substrate mechanism
has not yielded a clear answer either (Reyes and Tavoulari, 2011;
Lim and Miller, 2012). The function of the vestibular site in
MATs and other LeuT-fold transporters is thus still a subject of
debate.
Occlusion of the Central Binding Site
from the Extracellular Side
From electron paramagnetic resonance experiments it has been
shown that LeuT without substrate and ions bound ﬂuctuates
between outward- and inward-facing conformations, and that
the binding of Na+ stabilizes the outward open conformation,
which is thought to trigger the binding of substrate (Claxton et al.,
2010). In MD simulations it has been observed that when DA
is bound in the primary binding site of rDAT or hDAT along
with ions, the residues in the external gate (R85-D476 in hDAT)
come together and form a salt bridge (Huang and Zhan, 2007;
Huang et al., 2009; Gedeon et al., 2010; Stockner et al., 2013;
Figure 9). On the other hand, MD simulations of rDAT without
DA bound show no stable closure of the external gate which is
congruent with the observation that the ions alone stabilize the
outward open conformation of the transporter (Gedeon et al.,
2010). Similar results have been observed for 5-HT binding to
hSERT (Koldsø et al., 2011). A second extracellular gate has been
described which consists of a hydrophobic lid directly above
the primary binding site (Yamashita et al., 2005). In hDAT, the
lid is formed by F320 and Y156, and in addition, the nearby
residues F155 and Y84 have also been proposed to be part of this
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FIGURE 9 | Extracellular and intracellular gates. The residues suggested to be involved in the extracellular and intracellular gating networks are shown in sticks
with the carbon atoms in purple. In cartoon is shown TM1 (red), TM3 (yellow), TM5 (lime), TM6 (green), TM8 (cyan), and TM10 (blue). The residue indices are given in
red for hSERT, blue for hDAT, and green for hNET. The figure is based on a homology model of hDAT (Koldsø et al., 2013a).
hydrophobic gate (Stockner et al., 2013). It has been observed that
the average root-mean-square deviation (RMSD) of Cα atoms
in loop segments change depending on whether or not DA is
bound to rDAT during 15-20 ns MD simulations compared to
the original conformation of the homology model used in the
simulations (Gedeon et al., 2010). It was found that binding of
DA increased the average RMSD of Cα atoms in a segment of
EL2 by as much as 11 Å while lowering the RMSD of residue
512 in IL5 by almost 6 Å compared to simulations without
DA. In fact, the segment of EL2 consisting of residues 186-
203 (186-203 in hDAT) all had an average RMSD of at least
12 Å (Gedeon et al., 2010); however, this segment of EL2 was
modeled ab initio due to the fact that the template, LeuT, has
a shorter EL2 compared to the human MATs. The large RMSD
values suggest that the modeled conformation of the segment is
inaccurate, thus leading to artiﬁcially large movements during
MD simulations. It was also observed that the N-terminal helical
part of EL4, which is close to EL2, unwinds when DA is bound
to rDAT during 30 ns MD simulations (Gedeon et al., 2010).
A study by Stockner et al. (2013) found that it is possible to
stabilize the movements of EL2 in hDAT by modeling hDAT
while constraining the inducible Zn2+ site of hDAT. By creating
a homology model using this restraint they observed that W184
anchors itself into the head groups of the extracellular leaﬂet,
which in turn stabilizes the rest of EL2 in a conformation that
is able to bind Zn2+ steadily for 200 ns, thus bringing the
RMSD of EL2, with respect to the initial structure, down to
a level comparable to the RMSD of the remaining loops. It is
known that Zn2+ modulates hDAT by stabilizing the outward-
facing conformation (Richﬁeld, 1993) which suggests that the
movement of EL2 is necessary for the conformational change
from an extracellular to an intracellular facing conformation.
In spite of this, solvation of the ion in the Na2 site from
the intracellular side was observed along with closure of the
extracellular gates (Stockner et al., 2013). Solvation of the Na2
site from the intracellular side has also been observed for hDAT
in a study by Shan et al. (2011) using SMD (Shan et al., 2011),
where they observe that a rotation of S262 and M424 is needed
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to enable the intracellular solvent to diﬀuse in to the Na2
site.
Intracellular Opening and Release of
Substrate and Ions
To allow the release of substrate and ions to the intracellular
side, an intricate internal gating network has to open. Several
gating systems have been proposed and diﬀerent networks have
been observed in crystal structures of LeuT and dDAT, however,
it is diﬃcult to determine which of them are actual gates and
which are crystal artifacts, as well as their relevance for the human
MATs. Several studies have found F76, F69, and F332 (Shan et al.,
2011; Dehnes et al., 2014), and possibly also Y335 (Stockner
et al., 2013; Dehnes et al., 2014) and W63 (Dehnes et al., 2014)
in hDAT to form a hydrophobic cluster just below the primary
binding site. By steering the substrate toward the cytoplasm in
SMD simulations, it has been observed that these hydrophobic
residues can rotate away from each other allowing for DA to
move out of the binding site toward the cytoplasm (Shan et al.,
2011; Dehnes et al., 2014). The rotation of F332 pushes F69 in
TM1a resulting in TM1amoving away from TM6b and the center
of the protein allowing for the next gating system to open. An
intracellular gating network formed by several hydrogen bonds
between residues has also been reported (Kniazeﬀ et al., 2008)
(see Figure 9). Guptaroy et al. (2009) report hydrogen bonding
in hDAT between the backbone carbonyl of T62 and K260 and
the sidechain hydroxyl group of T62 and the backbone carbonyl
of Y335, which eﬀectively links TM1 and TM6 together through
interactions with the N-terminus, to be stable throughout 16 ns
of MD simulation of hDAT in an outward-facing conformation.
On the other hand, Dehnes et al. (2014) report stable hydrogen
bonding between K65 and N340, thus linking TM1 to TM7, in
MD simulations of the outward open hDAT during 5 ns. They
also observe that this hydrogen bond is not present throughout
5 ns of simulation of hDAT in an inward open conformation
(Dehnes et al., 2014). It should be noted that the just mentioned
simulations are rather short (5–16 ns), which makes it diﬃcult
to asses the stability of the observed interactions on longer time
scales. Another hydrogen bond between Y335 and E428 (in TM6
and TM8, respectively) has been reported to break due to rotation
of Y335 when performing simulations of the conformational
change from outward- to inward-facing hDAT using SMD (Shan
et al., 2011). Unbiased MD simulations of hSERT similarly reveal
that the interaction between the corresponding residues, namely
Y350 and E444, is lost during the transition from outward-facing
to inward-facing (Koldsø et al., 2011, 2013b). Additionally, the
solvated N-terminal close to TM1a and the intracellular loop
directly after TM8 (IL4) are also suggested to be connected by
a salt bridge interaction. This salt bridge is present in most of
the outward-facing crystal structures of dDAT (Penmatsa et al.,
2013, 2015;Wang et al., 2015) and has also been observed to break
during the transition toward the inward-facing conformation in
MD simulations of both hDAT (R60 and D436) (Stockner et al.,
2013) and hSERT (R79 and D452) (Koldsø et al., 2011). To
allow complete release of substrate, this salt bridge most likely
breaks, although it may be diﬃcult to observe in MD simulations
due to the common truncation of the terminals. In most MD
studies the N-terminal is truncated shortly before the N-terminal
arginine thus perhaps over-stabilizing the salt bridge by lack of
alternative interactions by the N-terminal residues not included
in the model.
Full release of substrate from either of the MATs has not
yet been observed in equilibrium MD simulations. However,
the conformational change from outward-facing to inward-
facing has been observed in unbiased MD simulations of hSERT,
followed by the release of Na+ from the Na2 site (Koldsø
et al., 2011, 2013b). In all three MATs, the Na2 site contains
an aspartate residue and for hSERT rotation of the side chain
of this residue, D437, was observed to pull the ion out of
the Na2 site and into the intracellular release pathway located
between TM1, 5, 6, and 8 (Koldsø et al., 2011). Based on
this observation, uptake experiments were performed with the
D437N mutant. As expected, a large increase in the Km value for
Na+ was obtained for the mutant, stressing the importance of
this residue for Na+ binding. On the other hand, similar values
of Km and Vmax for 5-HT transport were obtained for wild type
and D437N. Overall, this suggest that the Na+ ion in the Na2
site drives the transport of substrate, and that release of Na+
occurs prior to substrate release. Based on observations from
MD simulations of hSERT, the conformational change between
outward- and inward-facing can be described as a movement of
the helices of the bundle with respect to the scaﬀold (Koldsø et al.,
2011, 2013b), in accordance with the rocking bundle mechanism
(Forrest et al., 2008). However, the simulations suggest that
while the extracellular ends of helices in the bundle move in a
concerted fashion, intracellular opening is mainly due to a hinge-
type motion of TM1 and TM6, which have unwound central
parts.
Release of DA to the cytoplasm has been observed to occur
through two diﬀerent paths in RAMD simulations of rDAT
(Merchant and Madura, 2012); a pathway along TM6b and
TM8 was observed to occur twice as often as the alternative
pathway along TM1a and TM6b during 50 MD simulations of
0.1–0.7 ns duration. The latter pathway is similar to the one
reported by Koldsø et al. (2011) for Na+ release. They also
performed RAMD simulations of rDAT with DA occupying both
the primary and the vestibular binding site, but were not able
to determine conclusively if inward release of DA is improved
by the vestibular site being occupied by DA since DA release
was observed through four diﬀerent pathways, and only a few
times through each pathway. Shan et al. (2011) applied SMD to
sample the inward release of DA, and found the exit pathway
to be through the center of TM1, 5, 6, and 8, as both Koldsø
et al. (2011) and Merchant and Madura (2012) have proposed,
when alternating between SMD (2 ns intervals) and MD (4 ns
intervals) simulations of hDAT (Dehnes et al., 2014). It was
observed that rotamer changes in F76 and F322 allowDA tomove
from the primary binding site toward the intracellular milieu.
The rotation of F332 provokes movement of F69 resulting in
a signiﬁcant movement of TM1a away from TM6b followed by
breaking of a hydrogen bond between Y335 and E428 allowing
continued movement of TM1a and the N-terminus away from
TM6. They observe that water is able to move all the way to
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the primary binding site when simulations are performed with
a DA molecule in each of the two sites whereas in simulations
of hDAT with a single DA occupying the primary site, water
is only able to access F332, which is approximately half way
toward the primary binding site, (Shan et al., 2011; Dehnes et al.,
2014). Thus the results indicate that substrate binding in the
vestibular site may accelerate inward opening of hDAT. They
argue that the DA molecule occupying the primary binding site
increases its interaction with water when the vestibular site is also
occupied due to a rotation of S262 and M424 that allows water
to move toward the Na2 site from the intracellular side. Before
DA is released to the cytoplasm they observe an interaction with
E428 where DA is otherwise fully solvated and they propose this
interaction to be the last stabilizing interaction between DA and
hDAT before inward release.
CONCLUSION
In this review we have demonstrated the progress in our
understanding of MATs that has been based either directly or
indirectly on MD simulations. Despite limitations due to force
ﬁeld accuracy and restricted sampling, the discussed studies show
that MD simulations can shed light on the dynamic binding
of substrates and ions as well as diﬀerent types of inhibitors.
Furthermore, it is possible to directly observe the initial steps of
the mechanism of action of substrates and inhibitors in unbiased
MD simulations, but also full release of substrate using enhanced
sampling methods such as SMD or RAMD can be explored. It has
been possible to observe both speciﬁc residue–residue interaction
changes as well as large helix movements, e.g., when changing
from an outward-facing conformation, through occluded states,
until reaching an inward-facing conformation. In numerous
cases, the results of MD studies have guided the design of new
experiments and it is clear that combining MD simulations
and biochemical experiments is beneﬁcial for improving our
understanding of both transporter action and inhibition. The
established binding modes and behavior of neurotransmitters
within MATs can greatly aid in structure-based development of
new pharmaceutical drugs as well as in the ongoing optimization
of existing drugs.
Only 8 years has passed since the ﬁrst article containing
an MD simulation of a MAT based on a LeuT-fold template
was published (Yamashita et al., 2005), and the progress in
sampling and force ﬁeld accuracy has advanced enourmously
since then (Weng and Wang, 2014; Bernardi et al., 2015; Perilla
et al., 2015). Today, it is possible to calculate MD trajectories
of biological systems of several μs per day on custom built
supercomputers such as Anton (Dror et al., 2012), and advances
in computer design has made μs time scales feasible even on
ordinary computer clusters. Together with improved accuracy of
force ﬁelds regarding proteins (Lindorﬀ-Larsen et al., 2010; Best
et al., 2012) as well as lipids (Klauda et al., 2010; Dickson et al.,
2014) and ligands (Vanommeslaeghe et al., 2010; Mayne et al.,
2013), the great progress that has been observed thus far is still
only at the beginning stages of what will come in the future.
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